Publication | Closed Access

Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials

Drug SafetyAdverse EventsPulmonary TuberculosisTuberculosis PreventionPatient SafetyLatent Tuberculosis InfectionTuberculosisMedicineAdverse Drug ReactionEpidemiologyPharmacoepidemiologyPost-hoc Safety Analysis